Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer

Trial Profile

Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Eribulin (Primary) ; Olaparib (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 25 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Results (n=14) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top